vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Dominari Holdings Inc. (DOMH). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $16.1M, roughly 1.9× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -438.1%, a 430.4% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 27.3%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
DERM vs DOMH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $30.1M |
| Net Profit | $-1.2M | $-131.8M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | -8.9% |
| Net Margin | -7.8% | -438.1% |
| Revenue YoY | 27.3% | 220.4% |
| Net Profit YoY | -182.0% | -12426.2% |
| EPS (diluted) | $-0.04 | $-6.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $30.1M | ||
| Q3 25 | $17.0M | $50.8M | ||
| Q2 25 | $15.0M | $34.1M | ||
| Q1 25 | $13.1M | $8.1M | ||
| Q4 24 | $12.6M | $9.4M | ||
| Q3 24 | $14.6M | $4.0M | ||
| Q2 24 | $14.9M | $6.2M | ||
| Q1 24 | $13.0M | $1.4M |
| Q4 25 | $-1.2M | $-131.8M | ||
| Q3 25 | $-2.3M | $125.2M | ||
| Q2 25 | $-3.8M | $16.6M | ||
| Q1 25 | $-4.1M | $-32.5M | ||
| Q4 24 | $1.5M | $1.1M | ||
| Q3 24 | $-2.4M | $-4.2M | ||
| Q2 24 | $-3.4M | $-6.1M | ||
| Q1 24 | $-10.4M | $-5.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | -8.9% | ||
| Q3 25 | -9.0% | -3.1% | ||
| Q2 25 | -19.2% | -57.0% | ||
| Q1 25 | -25.3% | -394.6% | ||
| Q4 24 | 17.7% | 0.4% | ||
| Q3 24 | -19.8% | -79.1% | ||
| Q2 24 | -19.7% | -44.3% | ||
| Q1 24 | -77.4% | -205.2% |
| Q4 25 | -7.8% | -438.1% | ||
| Q3 25 | -13.6% | 246.4% | ||
| Q2 25 | -25.3% | 48.7% | ||
| Q1 25 | -31.0% | -400.5% | ||
| Q4 24 | 12.1% | 11.4% | ||
| Q3 24 | -16.3% | -104.2% | ||
| Q2 24 | -22.6% | -99.1% | ||
| Q1 24 | -80.1% | -398.0% |
| Q4 25 | $-0.04 | $-6.94 | ||
| Q3 25 | $-0.09 | $7.27 | ||
| Q2 25 | $-0.16 | $1.12 | ||
| Q1 25 | $-0.18 | $-3.02 | ||
| Q4 24 | $0.10 | $0.21 | ||
| Q3 24 | $-0.12 | $-0.67 | ||
| Q2 24 | $-0.17 | $-1.01 | ||
| Q1 24 | $-0.53 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $80.5M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $69.4M |
| Total Assets | $94.6M | $112.9M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $80.5M | ||
| Q3 25 | $24.9M | $176.2M | ||
| Q2 25 | $20.3M | $28.2M | ||
| Q1 25 | $21.1M | $18.9M | ||
| Q4 24 | $20.3M | $8.2M | ||
| Q3 24 | $22.5M | $7.2M | ||
| Q2 24 | $23.9M | $12.1M | ||
| Q1 24 | $24.1M | $7.1M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $69.4M | ||
| Q3 25 | $25.9M | $210.2M | ||
| Q2 25 | $19.2M | $88.6M | ||
| Q1 25 | $21.5M | $42.4M | ||
| Q4 24 | $20.1M | $39.9M | ||
| Q3 24 | $10.9M | $38.3M | ||
| Q2 24 | $11.3M | $42.4M | ||
| Q1 24 | $13.0M | $47.7M |
| Q4 25 | $94.6M | $112.9M | ||
| Q3 25 | $85.2M | $223.4M | ||
| Q2 25 | $81.2M | $109.3M | ||
| Q1 25 | $85.0M | $52.3M | ||
| Q4 24 | $80.2M | $47.1M | ||
| Q3 24 | $64.0M | $43.4M | ||
| Q2 24 | $65.2M | $49.1M | ||
| Q1 24 | $66.6M | $52.2M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $22.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $22.7M | ||
| Q3 25 | $-2.4M | $-4.9M | ||
| Q2 25 | $-942.0K | $-353.0K | ||
| Q1 25 | $-2.8M | $1.2M | ||
| Q4 24 | $2.2M | $-16.7M | ||
| Q3 24 | $-1.2M | $-4.7M | ||
| Q2 24 | $-5.2M | $1.4M | ||
| Q1 24 | $-5.0M | $-8.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | -15.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
